The ROS1 gene is located on 6q22.1 and encodes a receptor tyrosine kinase. Translocations affecting ROS1 have been detected in glioblastoma, cholangiocarcinoma, and non-small cell lung cancer (NSCLC). In NSCLC several ROS1 translocation partners have been detected all of which result in the fusion of variably truncated forms of e.g. TPM3, SDC4, SLC34A2, CD74, EZR, or LRIG3 to the kinase domain of ROS1. GOPC has also been found to be fused to ROS1 in NSCLC. GOPC-ROS1 fusions result from interstitial deletion of approx. 240 kb on 6q22.1. ROS1 rearrangements are thought to define a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK rearranged NSCLC. First evidence suggests that administration of ROS1 kinase inhibitors may represent a very effective therapeutic strategy in NSCLC patients harboring activating ROS1 rearrangements. Accordingly, detection of ROS1 rearrangements using Fluorescence in situ Hybridization might be a helpful tool for the identification of patients likely to respond to ROS1 kinase targeting therapies.